Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 11Recruiting 4Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3CNS 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 3Glioma 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × erdafitinib × 90 days × Clear all
NCT05316155 2026-06-05

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Janssen Research & Development, LLC

Phase 1/2 Recruiting
235 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-06-05

MoonRISe-1

Janssen Research & Development, LLC

Phase 3 Recruiting
641 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

Janssen Research & Development, LLC

Phase 3 Recruiting
220 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05859334 2026-06-02

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡